Spero Therapeutics
(NASDAQ) SPRO
Spero Therapeutics Financials at a Glance
Market Cap
$124.49M
Revenue (TTM)
$54.77M
Net Income (TTM)
$15.24M
EPS (TTM)
$0.24
P/E Ratio
8.82
Dividend
$0.00
Beta (Volatility)
0.94 (Low)
Dividend
$0.00
Beta (Volatility)
0.94 (Low)
Price
$2.12
Volume
766,217.17
Open
$2.15
Price
$2.12
Volume
766,217.17
Open
$2.15
Previous Close
$2.15
Daily Range
$2.12 - $2.23
52-Week Range
$1.80 - $3.22
Estimated Earnings Date
Aug 11, 2026
Dividend
$0.00
Beta (Volatility)
0.94 (Low)
Price
$2.12
Volume
766,217.17
Open
$2.15
Previous Close
$2.15
Daily Range
$2.12 - $2.23
52-Week Range
$1.80 - $3.22
Estimated Earnings Date
Aug 11, 2026
SPRO News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Spero Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
25
CEO
Esther Rajavelu, MBA
Website
www.sperotherapeutics.comHeadquarters
Cambridge, MA 02139, US
SPRO Financials
Key Financial Metrics (TTM)
Gross Margin
100.00%
Operating Margin
24.66%
Net Income Margin
27.82%
Return on Equity
35.58%
Return on Capital
-0.04%
Return on Assets
25.81%
Earnings Yield
11.34%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$124.49M
Shares Outstanding
57.90M
Volume
766.22K
Avg. Volume
932.77K
Financials (TTM)
Gross Profit
$54.77M
Operating Income
$13.51M
EBITDA
$14.89M
Operating Cash Flow
$7.24M
Capital Expenditure
$0.00
Free Cash Flow
$7.24M
Cash & ST Invst.
$56.13M
Total Debt
$2.47M
Spero Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$258.00K
-95.6%
Gross Profit
$258.00K
+103.3%
Gross Margin
100.00%
N/A
Market Cap
$124.49M
N/A
Market Cap/Employee
$3.89M
N/A
Employees
32
N/A
Net Income
-$7.20M
+48.1%
EBITDA
-$7.20M
+50.5%
Quarterly Fundamentals
Total Cash
$56.13M
+14.8%
Total Debt
$2.47M
-37.5%
Accounts Receivable
$44.00K
-99.8%
Inventory
$0.00
N/A
Long Term Debt
$507.00K
-76.6%
Short Term Debt
$1.97M
+9.6%
Return on Assets
25.81%
N/A
Return on Invested Capital
25.23%
N/A
Free Cash Flow
$15.86M
+496.4%
Operating Cash Flow
$15.86M
+496.4%